Low Disease Activity and Drug-Free Remission in Anti- MDA5 Dermatomyositis
Year: 2026
Type: article
Study design: Observational Study
Abstract: Importance: Anti-melanoma differentiation-associated gene 5 (MDA5)-positive dermatomyositis (MDA5-DM) is associated with rapid progression and high early mortality, but long-term outcomes beyond the early high-risk phase remain poorly characterized. Objective: To evaluate the attainability, associated factors, and durability of low disease activity (LDA) and drug-free remission (DFR) in patients with MDA5-DM. Design, Setting, and Participants: This retrospective cohort study at a tertiary referral center in China included consecutive patients with MDA5-DM who were enrolled between August 2003 and July 2023 and followed up through August 2025. Median follow-up was 5.7 (IQR, 3.4-7.4) years. The data were analyzed from September 2025 through December 2025. Exposures: Baseline demographic, clinical, and laboratory characteristics. Main Outcomes and Measures: Primary outcomes were experiencing LDA and DFR. Secondary outcomes included relapse after LDA or DFR and patient-reported outcomes assessed using the Patient Global Assessment and Health Assessment Questionnaire Disability Index. Results: Of 561 screened patients, 523 (93.2%) were included. Among 523 patients with MDA5-DM, 345 (65.9%) were female, 178 (34.1%) were male, and the median age at disease onset was 50.0 years (IQR, 41.0-57.5 years). Interstitial lung disease was present in 488 patients (93.3%) at baseline. Cumulative 1-, 3-, 5-, and 10-year all-cause mortality was 28.1%, 30.5%, 30.8%, and 31.7%, respectively. The 1-, 3-, 5-, and 10-year cumulative incidences of LDA were 3.1%, 47.1%, 59.0%, and 66.8%, respectively; corresponding incidences of DFR were 0%, 5.0%, 15.1%, and 31.0%, respectively. The median time from enrollment was 23 months (IQR, 18-34) for LDA and 46 months (IQR, 37-67) for DFR. Respiratory failure was associated with lower rates of LDA (subdistribution hazard ratio [sHR], 0.31; 95% CI, 0.19-0.51) and DFR (sHR, 0.33; 95% CI, 0.12-0.87), whereas a higher CD8-positive T-cell count was associated with higher rates of LDA (sHR, 1.15; 95% CI, 1.08-1.22) and DFR (sHR, 1.19; 95% CI, 1.09-1.31). The 5-year relapse-free probabilities were 76.7% after LDA and 82.0% after DFR. LDA and DFR were associated with lower Patient Global Assessment and Health Assessment Questionnaire Disability Index scores compared with non-LDA or non-DFR states. Conclusions and Relevance: The findings of this cohort study suggest that LDA was an attainable and durable long-term outcome for many patients with MDA5-DM, whereas DFR occurred less frequently. These findings may inform long-term disease control targets and treatment expectations in MDA5-DM.
Source: JAMA Dermatology
Authors: Xiaoqin Luo, Chen Zong, Huihui Ji, Shanshan Li, Yiran Chen, Longyang Zhu, Xinxin Zhang, Yunfeng Dai, Lin Luo, Ying Li, Qi Pan, Xinyue Xiao, Wei Jiang, Yongpeng Ge, Linrong He, Fang Chen, Chunjia Li, Lin Liang, Shanshan Li, Sizhao Li, Xia Liu, Xiaolan Tian, Hanbo Yang, Lu Zhang, Xiaoming Shu, Xin Lu, Guochun Wang, Qinglin Peng
Language: English
Subfield: Rheumatology
Field: Medicine
Domain: Health Sciences
Keywords: anti-MDA5 dermatomyositis, low disease activity, drug-free remission, interstitial lung disease, respiratory failure, relapse, disease progression, mortality, long-term outcomes, disease-modifying therapy, corticosteroid withdrawal, patient-reported outcomes, disease activity assessment, prognostic factors
Open Access status: green
OpenAlex ID: W7125598695
